A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.

NCT Number	NCT07297212
Lead Sponsor	BioNTech SE Collaborators: Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Conditions	Recurrent Glioblastoma
Enrollment	75 participants
Start Date	2026-01-15
Primary Completion	2028-01 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-29